To explore the application value of the levels of amphotericin (AREG) and mesothelin (MSLN) in the auxiliary diagnosis of breast cancer. Serum samples were collected from 46 patients with pathological diagnosis of suspected breast cancer and 46 healthy controls, and the levels of AREG and MSLN were measured by enzyme-linked immunosorbent assay (ELISA) and other methods to analyse their relationship with clinicopathological features of breast cancer, and the diagnostic efficacy of the two individually and in combination was evaluated by statistical methods. Serum AREG and MSLN levels were significantly higher in breast cancer patients than in healthy controls, and they were correlated with clinicopathological features such as pathological type, lymph node metastasis and pathological stage. The diagnostic accuracy of the combined test was higher than that of the individual test. AREG and MSLN levels are valuable in the adjuvant diagnosis of breast cancer, and the combination of these two tests is expected to improve the early diagnosis of breast cancer and provide a more reliable basis for clinical treatment decisions.

Kaiqian Liu, Shunfu Deng, Changshan Song. The value of AREG and MSLN levels in the adjuvant diagnosis of breast cancer. Academic Journal of Medicine & Health Sciences (2025), Vol. 6, Issue 1: 52-56. https://doi.org/10.25236/AJMHS.2025.060108.

[1] J H B, G C, B T, et al. Customizing Local And Systemic Therapies For Women With Early Breast Cancer: The St. Gallen International Consensus Guidelines for the treatment of early breast cancer 2021. [J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2021, 32(10):1216-1235.

[2] Huang Y, Shen S, Xiao J, et al. Mesothelin-targeted MRI for assessing migration, invasion, and prognosis in malignant pleural mesothelioma[J].Cancer Nanotechnology (1868-6958), 2024, 15(1).DOI:10.1186/s12645-023-00238-y.

[3] Ramalingam P S, Premkumar T, Sundararajan V,et al.Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches[J].Discover Oncology, 2024, 15(1):1-17. DOI:10.1007/s12672-024-01455-6.

[4] Li J, Han GH. Research progress of mesothelin in the diagnosis and treatment of malignant tumours[J]. Cancer Progress, 2021, 19(09):882-886. 

[5] Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets [J].Seminars in Cancer Biology, 2020, 60(prepublish):14-27.

[6] L. G A, Gabriel C, Shenae S, et al. Assessment of Textbook Oncologic Outcomes Following Modified Radical Mastectomy for Breast Cancer [J]. Surgical Research, 2022, 27717-26.

[7] Nicoletti A, Vitale F, Quero G,et al. Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adenocarcinoma[J].Cancers, 2023, 15(18).DOI:10.3390/cancers15184586.

[8] Xu Yuan, Kaidi Li, BING Zhongxing, et al. Role of bimodulin in tumourigenesis and progression[J]. Journal of Concordant Medicine, 2017, 8(01):56-60. 

[9] LIU Pohan, LIU Shimen, HE Yiqing, et al. The value of serum bimodulin and mesothelin in the adjuvant diagnosis of breast cancer[J]. Laboratory Medicine, 2024, 39(01):26-30.